CSPC Megalith Biopharmaceutical Co., Ltd.
Clinical trials sponsored by CSPC Megalith Biopharmaceutical Co., Ltd., explained in plain language.
A biopharmaceutical subsidiary of CSPC Pharmaceutical Group, focusing on drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo aims to shrink lung tumors before surgery Results expected Nov 2026 (estimated)
- New drug combo aims to fight resistant lung cancer Results expected Dec 2026 (estimated)
- Could a new injection help tackle obesity? a safety trial begins Results expected Feb 2027 (estimated)
- New mRNA shingles vaccine enters phase 2 trial – could it be a game changer? Results expected Mar 2027 (estimated)
- Can a smart drug deliver a direct hit to Hard-to-Treat tumors? Results expected Mar 2027 (estimated)
-
New drug cocktail aims to shrink recurrent ovarian tumors
Disease control Recruiting nowThis phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a smart drug deliver a direct hit to Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SYS6041 in people with advanced solid tumors. SYS6041 is designed to seek out and attach to a protein called FRα that is found on some cancer cells, delivering a potent anti-cancer agent directly to the tumor. The study aims to fi…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control Recruiting nowThis Phase 3 trial tests a new drug called SYS6010 against standard chemotherapy in 380 people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted therapy. The goal is to see if SYS6010 can delay cancer growth better than chemo. Par…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests two drugs together for people with advanced breast cancer that cannot be removed by surgery. SYS6023 targets a protein called HER3 on cancer cells, while KN026 targets HER2. The goal is to see if the combination is safe and shrinks tumors. About 36 adults with co…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted drug SYS6043 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug duo takes on tough head and neck cancer
Disease control Recruiting nowThis Phase 2 trial is testing whether a combination of two drugs, SYS6010 and Enlonstobart, can shrink tumors or slow the growth of head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for their advanced cancer wi…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC